Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23167084 | 0.79 | KAT6A (0.36) | KMOPPARAKAT6ALRRK2 | |
| SCHEMBL70649 | 0.74 | KMO (0.37) | KMOPPARA | |
| SCHEMBL5584076 | 0.72 | AHR (0.35) | — | |
| SCHEMBL1545373 | 0.71 | IDO1 (0.46) | KMOKAT6A | |
| SCHEMBL15637876 | 0.70 | HDAC3 (0.35) | — | |
| SCHEMBL1404517 | 0.70 | L3MBTL1 (0.57) | — | |
| SCHEMBL3398203 | 0.70 | KMO (0.47) | KMOFAAHKCNH2SLC2A1 | |
| SCHEMBL493735 | 0.70 | KMO (0.44) | KMOPPARAFAAHKCNH2SLC2A1 | |
| SCHEMBL29045053 | 0.68 | PPARA (0.40) | KMOPPARA | |
| SCHEMBL17984217 | 0.66 | GP6 (0.44) | KMOPPARAKAT6ALRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999107-B2 | Psychological disorders; cognition activators; Alzheimer's disease; headaches; nervous system antiinflammatory agents; antiepileptic agents; Parkinson's disease; Huntington's disease; schizophrenia; eating disorders | MERCK SHARP & DOHME CORP. (US) | 2011-08-16 | — | — | US | disclosed |
| EP-2109615-B1 | SUBSTITUTED PYRANO [2, 3 - B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-03-09 | — | — | EP | disclosed |
| EP-2109615-A1 | SUBSTITUTED PYRANO [2, 3 - B]PYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. | 2008-08-28 | — | — | US | disclosed |
| WO-2008094476-A1 | SUBSTITUTED PYRANO [2, 3 - B] PYRIDINE DERIVATIVES AS CANNABINOID -1 RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207666-A1 | Substituted pyrano[2,3-B]pyridine derivatives as cannabinoid-1 receptor modulators | CNR1, CNR2, FAAH | KMO 473/4885PPARA 179/4885FAAH 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.